ASH 2022 | Acalabrutinib vs ibrutinib in R/R CLL: assessing the burden of adverse events
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, describes the results of a post-hoc analysis of the adverse event (AE) burden of acalabrutinib and ibrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in a Phase III head-to-head trial (NCT02477696). The results of this analysis further support the superior tolerability of acalabrutinib compared with ibrutinib and confirm the safety differences that have been reported previously between the two drugs, including lower AE burden scores for hypertension and hemorrhage in patients treated with acalabrutinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm Therapeutics: Research Funding; Schrodinger: Research Funding; Newave: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; ArQule: Consultancy; MorphoSys: Consultancy, Research Funding; Loxo@Lilly: Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy.
